Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

NEW YORK, December 30, 2025, 14:33 ET — Regular session

  • Accenture shares dipped in thin year-end trading as a brokerage cut its price target but kept a buy rating.
  • U.S. stocks were muted after Federal Reserve minutes highlighted divisions over the path for rates.
  • Investors are looking ahead to Accenture’s next earnings update in March.

Accenture plc shares were down about 0.5% on Tuesday, drifting lower in a quiet year-end session after Argus lowered its price target on the IT services company while maintaining a buy rating.

The move matters because Accenture is widely treated as a read-through on corporate technology spending, and late-December liquidity is thin. In that backdrop, even routine changes in analyst targets can move large-cap consulting names more than usual.

Traders were also navigating a fresh macro signal after Federal Reserve meeting minutes showed policymakers split over how quickly to keep easing policy, a debate that can feed into valuations for growth-linked stocks and the pace of client spending on big transformation projects. Reuters

Accenture was trading at $270.06, down $1.28 from its prior close. The stock traded between $269.54 and $272.25.

MT Newswires reported that Argus cut its price target on Accenture to $335 from $370, while keeping a buy rating. A price target is an analyst’s estimate of where a stock may trade over the next 12 months. MarketScreener

Broader market moves stayed restrained. The S&P 500 and Nasdaq were little changed in choppy trading, with investors repositioning out of heavyweight technology after a recent run, according to Reuters. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

Peers were mixed. IBM and Cognizant Technology Solutions were both down around 0.7% to 0.9%, while Booz Allen Hamilton was slightly higher.

The latest analyst move comes less than two weeks after Accenture reported quarterly results that beat Wall Street revenue expectations, helped by demand tied to AI-driven IT services. Accenture forecast second-quarter revenue of $17.35 billion to $18.0 billion, with the midpoint below analysts’ expectations, according to LSEG data cited by Reuters. Reuters

The Fed minutes released Tuesday showed that even some officials who supported the December rate cut saw the decision as “finely balanced,” while others worried progress toward the 2% inflation goal had stalled, Reuters reported. The minutes also flagged January 9 and January 13 as dates when delayed jobs and consumer price data for December are due, with the Fed’s next meeting set for January 27-28. Reuters

For Accenture, the next major scheduled company catalyst is its second-quarter fiscal 2026 earnings call on March 19, the company’s investor FAQ page shows. Accenture

Until then, traders are likely to take their cues from rate expectations, year-end flows and any fresh signs of how quickly clients are signing large multi-quarter programs — a key driver for consulting firms’ bookings, which represent future contracted work.

Stock Market Today

  • Two under-$10 stocks that could double in 2026: Opendoor Technologies and Sweetgreen
    December 30, 2025, 5:25 PM EST. Two under-$10 names could double in 2026: Opendoor Technologies and Sweetgreen. Through late December, Opendoor was up about 260% in 2025 after a management reshuffle and a turnaround plan aimed at break-even on adjusted net income by year-end 2026. With mortgage rates around 6% and signs housing demand could recover, the stock's upside hinges on macro strength and execution. Sweetgreen faces a tougher year, but easier year-over-year comparisons and potential improvements in same-store sales could spark a rebound if the broader economy cooperates. The prospect of a double is speculative and relies on favorable macro conditions; as of Dec. 29, 14 S&P 500 components had doubled this year.
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading
Previous Story

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%
Next Story

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Go toTop